Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 1907-1914

  Pruvost, Alain ^a   Negredo, Eugènia ^b   Benech, Henri ^a   Theodoro, Frédéric ^a   Puig, Jordi ^b   Grau, Eulàlia ^b   García, Elisabet ^b   Moltó, José ^b   Grassi, Jacques ^a   Clotet, Bonaventura ^b  

^a Institut National de la Recherche Agronomique   (France)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYADENOSINE TRIPHOSPHATE; 9 (2 PHOSPHONOMETHOXYPROPYL)ADENINE DIPHOSPHATE; DIDANOSINE; DRUG METABOLITE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS RESISTANCE;

ADENINE; ANTI-HIV AGENTS; CELL COUNT; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; DIDANOSINE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LONGITUDINAL STUDIES; MASS SPECTROMETRY; PHOSPHONIC ACIDS; PHOSPHORYLATION; REFERENCE STANDARDS;

EID: 20944435946     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.1907-1914.2005     Document Type: Article

References (21)

1. Ahluwalia, G., D. A. Cooney, N. R. Hartman, H. Mitsuya, R. Yarchoan, A. Fridland, S. Broder, and D. G. Johns. 1993. Anomalous accumulation and decay of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metab. Dispos. 21:369-376.
2. Becher, F., R. Landman, S. Mboup, C. N. Kane, A. Canestri, F. Liegeois, M. Vray, M. H. Prevot, G. Leleu, and H. Benech. 2004. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 18:181-187.
3. Becher, F., A. Pruvost, J. Gale, P. Couerbe, C. Goujard, V. Beutet, E. Ezan, J. Grassi, and H. Benech. 2003. A strategy for liquid chromatography/ tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J. Mass Spectrom. 38:879-890.
4. Becher, F., A. Pruvost, C. Goujard, C. Guerreiro, J. F. Delfraissy, J. Grassi, and H. Benech. 2002. Improved method for the simultaneous determination of d4T, 3TC and ddI intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:555-565.
5. Becher, F., A. G. Pruvost, D. D. Schlemmer, C. A. Creminon, C. M. Goujard, J. F. Delfraissy, H. C. Benech, and J. J. Grassi. 2003. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients. AIDS 17:555-561.
6. Benech, H., F. Theodoro, A. Herbet, N. Page, D. Schlemmer, A. Pruvost, J. Grassi, and J. R. Deverre. 2004. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 330:172-174.
7. Birkus, G., M. J. Hitchcock, and T. Cihlar. 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:716-723.
8. Blanchard, J. N., M. Wohlfeiler, A. Canas, K. King, and J. T. Lonergan. 2003. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. Clin. Infect. Dis. 37:e57-e62.
9. Havlir, D. V., C. Tierney, G. H. Friedland, R. B. Pollard, L. Smeaton, J. P. Sommadossi, L. Fox, H. Kessler, K. H. Fife, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182:321-325.
10. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41:1231-1236.
11. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595.
12. Martinez, E., A. Milinkovic, E. de Lazzari, G. Ravasi, J. L. Blanco, M. Larrousse, J. Mallolas, F. Garcia, J. M. Miro, and J. M. Gatell. 2004. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 364:65-67.
13. Murphy, M. D., M. O'Hearn, and S. Chou. 2003. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis. 36:1082-1085.
14. Negredo, E., J. Molto, D. Burger, P. Viciana, E. Ribera, R. Paredes, M. Juan, L. Ruiz, J. Puig, A. Pruvost, J. Grassi, E. Masmitja, and B. Clotet. 2004. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18:459-463.
15. Negredo, E., J. Molto, J. A. Munoz-Moreno, E. Pedrol, E. Ribera, P. Viciana, M. J. Galindos, C. Miralles, D. Burger, F. C. Rodriguez, J. Puig, S. Gel, E. Rodriguez, S. Videla, L. Ruiz, and B. Clotet. 2004. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir. Ther. 9:335-342.
16. Pecora, F. P., and M. A. Kirian. 2003. Effect of tenofovir on dldanosine absorption in patients with HIV. Ann. Pharmacother. 37:1325-1328.
17. Pruvost, A., F. Becher, P. Bardouille, C. Guerrero, C. Creminon, J. F. Delfraissy, C. Goujard, J. Grassi, and H. Benech. 2001. Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 15:1401-1408.
18. Ray, A. S., L. Olson, and A. Fridland. 2004. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48:1089-1095.
19. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42:612-617.
20. Robbins, B. L., C. K. Wilcox, A. Fridland, and J. H. Rodman. 2003. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23:695-701.
21. Salmon-Ceron, D., R. Lassalle, A. Pruvost, H. Benech, M. Bouvier-Alias, C. Payan, C. Goujard, E. Bonnet, F. Zoulim, P. Morlat, P. Sogni, S. Perusat, J. M. Treluyer, and G. Chene. 2003. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. Clin. Infect. Dis. 36:1295-1304.